Fluoroquinolones in ambulatory ENT and respiratory tract infections: rarely appropriate

Area of Science:

• Infectious Diseases
• Pharmacology
• Respiratory Medicine

Background:

• The use of antibiotics, particularly fluoroquinolones, in common respiratory and ear infections is widespread but debated.
• Evidence suggests fluoroquinolones may not offer superior efficacy compared to other antibiotic classes for many conditions.
• Concerns exist regarding the safety profile and adverse effects associated with fluoroquinolone use.

Purpose of the Study:

• To evaluate the appropriate role of fluoroquinolones in treating exacerbations of chronic bronchitis, community-acquired pneumonia, and acute sinusitis.
• To compare fluoroquinolones with first-line antibiotic options such as betalactams and macrolides.
• To highlight the adverse effects and contraindications of fluoroquinolone therapy.

Main Methods:

• This analysis is based on a review of current clinical guidelines and evidence regarding antibiotic use in respiratory tract infections.
• Comparative efficacy and safety data for fluoroquinolones versus betalactams (e.g., amoxicillin) and macrolides were assessed.
• Risk-benefit profiles and specific patient populations (e.g., children, pregnant women) were considered.

Main Results:

• Fluoroquinolones are considered second-line agents for chronic bronchitis exacerbations and acute sinusitis, with betalactams and macrolides being preferred first-line options.
• For community-acquired pneumonia, betalactams and macrolides are first-line; combination therapy including fluoroquinolones may be used for severe cases.
• Fluoroquinolones are associated with significant adverse effects, including neuropsychiatric, cutaneous, tendon, and cardiac issues, and are contraindicated in pregnancy.

Conclusions:

• Antibiotic therapy for chronic bronchitis exacerbations carries an uncertain risk-benefit ratio, with fluoroquinolones not being a preferred first choice.
• For community-acquired pneumonia, initial treatment should involve betalactams or macrolides, with fluoroquinolones reserved for specific situations.
• The use of fluoroquinolones in sinusitis, chronic sinusitis, and chronic otitis media is controversial, and they are not recommended as first-line agents due to their adverse effect profile.